Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 48 member 1 (SLC48A1; HRG1) is a protein-coding membrane transporter essential for intracellular heme transport and iron homeostasis. It is primarily located in the lysosomal and endosomal membranes, where it mediates the export of heme from the lumen to the cytoplasm during erythrophagocytosis in reticuloendothelial system macrophages. This process is vital for iron recycling from senescent red blood cells, supporting ongoing erythropoiesis and preventing iron deficiency or overload[2][3][4]. SLC48A1 is highly expressed in mature oligodendrocytes in the CNS, where it imports heme to support iron acquisition, with knockout models displaying myelin defects and impaired myelin-associated glycoprotein expression, linking its function to neural integrity and neurodegenerative risk[1]. Deficiency of SLC48A1 results in accumulation of hemozoin (a crystalline heme deposit) in macrophages, mirroring adaptations seen in certain parasites but leading to metabolic challenges and anemia in mammals[2]. Diseases associated with its malfunction include anemia, iron overload syndromes, neurodegeneration, and developmental disorders. Although there are currently no approved drugs that directly target SLC48A1, it is considered a critical transporter for therapeutic modulation of iron and heme metabolism in relevant disease contexts[2][3][4].
For experimental heme/iron modulators: Inhibition or enhancement of heme transport across lysosomal/endosomal membranes. Alteration of intracellular iron recycling in erythrophagocytosis. Impact on iron availability in myelination processes in CNS. Modulation of iron-dependent biosynthetic/catabolic pathways in cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 48 member 1 (SLC48A1).